Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-7058 + cetuximab
- Development stage
- Phase 2
- Lead developer
- Shandong Suncadia Medicine
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
HRS-7058 + cetuximab is a combination therapy under investigation for the treatment of advanced solid tumors, particularly those harboring KRAS G12C mutations. HRS-7058 is an orally administered, highly selective small molecule inhibitor targeting the KRAS G12C mutant protein, developed by Shandong Suncadia Medicine (a subsidiary of Jiangsu HengRui). Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is marketed under the brand name Erbitux. The combination aims to inhibit tumor growth through dual blockade of KRAS-driven signaling and EGFR-mediated pathways. Clinical trials are ongoing to evaluate safety, tolerability, pharmacokinetics, and efficacy in patients with advanced malignant tumors[1][2][4][5].
02
Targets
Beyond the preview
Go deeper on HRS-7058 + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-7058 + cetuximab.